Nephrogenic Systemic Fibrosis: Considerations for the Cardiologist**Editorials published in JACC: Cardiovascular Imaging reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Imaging or the American College of Cardiology.

JACC: Cardiovascular Imaging

Volumn 1, Issue 4, 2008, Pages 457-459

  Rofsky, Neil M ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

contrast media; gadolinium; nephrogenic systemic fibrosis; renal insufficiency; safety

Indexed keywords

GADODIAMIDE; GADOLINIUM; GADOTERIDOL;

CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CONTRAST ENHANCEMENT; EDITORIAL; FIBROSIS; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEMODIALYSIS PATIENT; HIGH RISK POPULATION; HUMAN; NEPHROGENIC FIBROSING DERMOPATHY; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

CARDIOVASCULAR DISEASES; CONTRAST MEDIA; FIBROSIS; GADOLINIUM DTPA; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MAGNETIC RESONANCE IMAGING, CINE; NEPHROGENIC FIBROSING DERMOPATHY; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 47349125137     PISSN: 1936878X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcmg.2008.05.007     Document Type: Editorial

References (20)

1. Schietinger B.J., Brammer G.M., Wang H., et al. Patterns of late gadolinium enhancement in chronic hemodialysis patients. J Am Coll Cardiol Img 1 (2008) 450-456
2. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 21 (2006) 1104-1108
3. Marckmann P., Skov L., Rossen K., et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17 (2006) 2359-2362
4. Sadowski E.A., Bennett L.K., Chan M.R., et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243 (2007) 148-157
5. Thomsen H.S., and Marckmann P. Extracellular Gd-CA: differences in prevalence of NSF. Eur J Radiol 66 (2008) 180-183
6. Cowper S.E., Robin H.S., Steinberg S.M., Su L.D., Gupta S., and LeBoit P.E. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356 (2000) 1000-1001
7. Daram S.R., Cortese C.M., and Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis 46 (2005) 754-759
8. Wiginton C.D., Kelly B., Oto A., et al. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. AJR Am J Roentgenol 190 (2008) 1060-1068
9. Wahba I.M., Simpson E.L., and White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant 7 (2007) 2425-2432
10. White G.W., Gibby W.A., and Tweedle M.F. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 41 (2006) 272-278
11. Wedeking P., Kumar K., and Tweedle M.F. Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. Magn Reson Imaging 10 (1992) 641-648
12. Rofsky N.M., Sherry A.D., and Lenkinski R.E. Nephrogenic systemic fibrosis: a chemical perspective. Radiology 247 (2008) 608-612
13. Kanal E., Broome D.R., Martin D.R., and Thomsen H.S. Response to the FDA's May 23, 2007 nephrogenic systemic fibrosis update. Radiology 246 (2008) 11-14
14. Reilly R.F. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol 3 (2008) 747-751
15. Kim R.J., Wu E., Rafael A., et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343 (2000) 1445-1453
16. Balci N.C., Inan N., Anik Y., Erturk M.S., Ural D., and Demirci A. Low-dose gadobenate dimeglumine versus standard-dose gadopentate dimeglumine for delayed contrast-enhanced cardiac magnetic resonance imaging. Acad Radiol 13 (2006) 833-839
17. Gupta A., Lee V.S., Chung Y.C., Babb J.S., and Simonetti O.P. Myocardial infarction: optimization of inversion times at delayed contrast-enhanced MR imaging. Radiology 233 (2004) 921-926
18. Wu M.T., Tseng W.Y., Su M.Y., et al. Diffusion tensor magnetic resonance imaging mapping the fiber architecture remodeling in human myocardium after infarction: correlation with viability and wall motion. Circulation 114 (2006) 1036-1045
19. Jansen M.A., Van Emous J.G., Nederhoff M.G., and Van Echteld C.J. Assessment of myocardial viability by intracellular 23Na magnetic resonance imaging. Circulation 110 (2004) 3457-3464
20. Beer M., Spindler M., Sandstede J.J., et al. Detection of myocardial infarctions by acquisition-weighted 31P-MR spectroscopy in humans. J Magn Reson Imaging 20 (2004) 798-802